Invesco DB Commodity Index Tracking Fund vs GeneDx Holdings Corp — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $30.03, while GeneDx Holdings Corp trades at $82.64 (market cap $2.44B). The key difference: Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| DBC | WGS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $31.69 | $167.51 |
52-Week Low | $21.62 | $34.51 |
Market Cap | — | $2.44B |
Enterprise Value | — | $2.48B |
Signals from Pluang's Aura AI — not financial advice
DBC trades at $30.00, up 0.23% with a bullish technical signal from moving averages. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights commodities ETFs as inflation hedges, with articles discussing portfolio strategies and geopolitical impacts on commodity markets.
The outlook is cautiously optimistic due to technical strength, but lack of fundamental data poses risks. Opportunities include commodity exposure for diversification, while risks involve market volatility and reliance on broader commodity trends without company-specific financial clarity.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Trailing returns across standard periods
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →